Diabetic nephropathy (DN) is one of the major complications that develop as consequence of chronic and uncontrolled hyperglycaemia. Hyperglycaemia initiates various processes, one of which is protein glycation, leading to the formation of advanced glycation end products. Alteration of intracellular signalling, gene expression, release of proinflammatory molecules and free radicals are examples of such changes and they contribute to the initiation of diabetic complications. In the current manuscript, we studied the effect of pyridoxamine (PM) on protein glycation, oxidative stress, interleukin-1α (IL-1α), IL-6, C-reactive protein (CRP), gene expression of tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1) in relation to microalbuminuria and kidney functions in a model of alloxan-induced diabetic rats. We have observed that onset of microalbuminuria has preceded the gradual increase of blood sugar level in diabetic rats. In diabetic rats, gene expression of TNF-α and TGF-β1 recorded a gradual increase and marked increase was observed after one and two weeks of alloxan administration, in comparison with normal rats. PM induced significant decrease in kidney malondialdehyde content and the gene expression of TNF-α and TGF-β1, in addition to levels of serum glucose, fructosamine, urea, creatinine, IL-1α, IL-6, CRP and urine microalbumin. Histopathological examination of kidney tissues showed certain improvements as compared with diabetic control. In conclusion, our results may provide a supporting evidence for the therapeutic benefit of PM in DN.
BreyerMDBottingerEBrosiusFCCoffmanTMFogoAHarrisRCHeiligCWSharmaK. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis2005; 12: 128–45.
2.
LewisEJGreeneTSpitalewizSBlumenthalSBerlTHunsickerLGPohlMARohdeRDRazIYerushalmyYYagilYHerskovitsTAtkinsRCReutensATPackhamDKLewisJB. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol2012; 23: 131–6.
3.
MoraCNavarroJF. Inflammation and diabetic nephropathy. Curr Diabetes Rep2006; 6: 463–8.
4.
Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int 2007:S49–53.
5.
AhmedN. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract2005; 67: 3–21.
6.
FriedmanEA. Continuously evolving management concepts for diabetic CKD and ESRD. Semin Dialysis2010; 23: 134–9.
7.
GhanimHAljadaAHofmeyerDSyedTMohantyPDandonaP. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation2004; 110: 1564–71.
8.
PickupJCChusneyGDThomasSMBurtD. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci2000; 67: 291–300.
9.
HotamisligilGSArnerPCaroJFAtkinsonRLSpiegelmanBM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Investig1995; 95: 2409–15.
10.
HotamisligilGSPeraldiPBudavariAEllisRWhiteMFSpiegelmanBM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science1996; 271: 665–8.
11.
StephensJMPekalaPH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem1991; 266: 21839–45.
12.
ZhangBBergerJHuESzalkowskiDWhite-CarringtonSSpiegelmanBMMollerDE. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol1996; 10: 1457–66.
13.
Navarro-GonzalezJFMora-FernandezCMuros de FuentesMGarcia-PerezJ. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol2011; 7: 327–40.
14.
EddyAA. Protein restriction reduces transforming growth factor-beta and interstitial fibrosis in nephrotic syndrome. Am J Physiol1994; 266: F884–93.
15.
ShanklandSJScholeyJWLyHThaiK. Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int1994; 46: 430–42.
16.
SinghRBardenAMoriTBeilinL. Advanced glycation end-products: a review. Diabetologia2001; 44: 129–46.
17.
SheplerBNashCSmithCDimarcoAPettyJSzewciwS. Update on potential drugs for the treatment of diabetic kidney disease. Clin Therapeut2012; 34: 1237–46.
U.S. Renal Data System: USRDS 2011 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011.
20.
ChuangaY-CWubM-SWucT-HSubY-KLeedY-M. Pyridoxamine ameliorates the effects of advanced glycation end products on subtotal nephrectomy induced chronic renal failure rats. J Func Foods2012; 4: 679–86.
DegenhardtTPAldersonNLArringtonDDBeattieRJBasgenJMSteffesMWThorpeSRBaynesJW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int2002; 61: 939–50.
23.
TanimotoMGohdaTKanekoSHagiwaraSMurakoshiMAokiTYamadaKItoTMatsumotoMHorikoshiSTominoY. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism2007; 56: 160–7.
24.
ChangKCLiangJTTsaiPSWuMSHsuKL. Prevention of arterial stiffening by pyridoxamine in diabetes is associated with inhibition of the pathogenic glycation on aortic collagen. Br J Pharmacol2009; 157: 1419–26.
25.
WilliamsMEBoltonWKKhalifahRGDegenhardtTPSchotzingerRJMcGillJB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol2007; 27: 605–14.
26.
HouseAAEliasziwMCattranDCChurchillDNOliverMJFineADresserGKSpenceJD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA2010; 303: 1603–9.
27.
ChetyrkinSVKimDBelmontJMScheinmanJIHudsonBGVoziyanPA. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int2005; 67: 53–60.
28.
CanningPGlennJVHsuDKLiuFTGardinerTAStittAW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res2007; 2007: 51837–51837.
ZhengFZengYJPlatiARElliotSJBerhoMPotierMStrikerLJStrikerGE. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int2006; 70: 507–14.
31.
DuryRAWallingtonEA. Histological techniques, 5th ed. New York: Oxford, 1980, pp. 27–9.
32.
TrinderP. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J Clin Pathol1969; 22: 246–246.
33.
SchleicherEDVogtBT. Standardization of serum fructosamine assays. Clin Chem1990; 36: 136–9.
34.
Henry RJ. Determination of serum creatinine. In: Clinical chemistry, principles and techniques. 2nd ed. New York: Harper and Row Publishers, 1974, p. 525..
35.
FawcettJKScottJE. A rapid and precise method for the determination of urea. J Clin Pathol1960; 13: 156–9.
36.
GallMARossingPSkottPDamsboPVaagABechKDejgaardALauritzenMLauritzenEHougaardPBeck-NielsenHParvingHH. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia1991; 34: 655–61.
37.
BanerjeeMTripathiLMSrivastavaVMPuriAShuklaR. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol2003; 25: 213–24.
38.
OhkawaHOhishiNYagiK. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem1979; 95: 351–8.
39.
WilliamsonJRChangKFrangosMHasanKSIdoYKawamuraTNyengaardJRvan denEndenMKiloCTiltonRG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes1993; 42: 801–13.
40.
HudsonBIBucciarelliLGWendtTSakaguchiTLallaEQuWLuYLeeLSternDMNakaYRamasamyRYanSDYanSFD'AgatiVSchmidtAM. Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys2003; 419: 80–8.
41.
NeumannASchinzelRPalmDRiedererPMunchG. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett1999; 453: 283–7.
42.
JonesSPhillipsAO. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int2001; 59: 1739–49.
43.
KoikeNTakamuraTKanekoS. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor. Life Sci2007; 80: 1721–8.
44.
McCarthyETSharmaRSharmaMLiJZGeXLDileepanKNSavinVJ. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol1998; 9: 433–8.
45.
PopaCNeteaMGvan RielPLvan der MeerJWStalenhoefAF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res2007; 48: 751–62.
46.
LangCHDobrescuCBagbyGJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology1992; 130: 43–52.
47.
JaattelaM. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Laboratory investigation. J Tech Meth Pathol1991; 64: 724–42.
48.
WuY-GLinHQiX-MWuG-ZQianHZhaoMShenJ-JLinS-T. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol2006; 6: 445–53.
49.
WolfGSharmaKChenYEricksenMZiyadehFN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int1992; 42: 647–56.
50.
ChenSJimBZiyadehFN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol2003; 23: 532–43.
51.
MonnierVMSellDRNagarajRHMiyataSGrandheeSOdettiPIbrahimSA. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes1992; 41: 36–41.
52.
SkolnikEYYangZMakitaZRadoffSKirsteinMVlassaraH. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med1991; 174(4): 931–9.
53.
MakitaZBucalaRRayfieldEJFuhHManogueKRCeramiAViassaraHFriedmanEAKaufmanAMKorbetSMBarthRHWinstonJA. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet1994; 343(8912): 1519–22.
54.
BergTJBangstadHJTorjesenPAOsterbyRBucalaRHanssenKF. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism1997; 46: 661–5.
55.
VoziyanPAKhalifahRGThibaudeauCYildizAJacobJSerianniASHudsonBG. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem2003; 278: 46616–24.
56.
ChetyrkinSMathisMHayes McDonaldWShackelfordXHudsonBVoziyanP. Pyridoxamine protects protein backbone from oxidative fragmentation. Biochem Biophys Res Commun2011; 411: 574–9.
57.
AdaikalakoteswariARabbaniNWaspadjiSTjokroprawiroAKariadiSHAdamJMThornalleyPJ. Disturbance of B-vitamin status in people with type 2 diabetes in Indonesia–link to renal status, glycemic control and vascular inflammation. Diabetes Res Clin Pract2012; 95: 415–24.
